Vera kidney drug Trutakna shows strong final results in Phase 3 trial
Vera Therapeutics' Trutakna met all endpoints in the final analysis of the Phase 3 ORIGIN 3 trial, preventing disease progression and stabilizing eGFR over 104 weeks. The drug, a weekly autoinjector that inhibits BAFF and APRIL, reduces proteinuria in high-risk adults with primary IgA nephropathy. The company presented these findings during the opening plenary and late-breaking sessions at the American Society of Nephrology Kidney Week 2026 in Denver. Trutakna works by decreasing immune complex formation and pathogenic IgA production while managing the effects of nephron loss.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Trutakna met all endpoints in the Phase 3 ORIGIN 3 final analysis.
- ✓ The ORIGIN 3 trial demonstrated eGFR stabilization and prevention of disease progression over 104 weeks.
- ✓ Trutakna is a weekly autoinjector BAFF and APRIL inhibitor.
- ✓ Vera Therapeutics presented the ORIGIN 3 data at the American Society of Nephrology Kidney Week 2026 in Denver.
What changed
Vera Therapeutics scheduled an investor webcast for October 22 to discuss the ORIGIN 3 efficacy results.
Live updates
-
Vera Therapeutics reports positive Phase 3 Trutakna results for IgA nephropathy
Vera Therapeutics' Trutakna met all endpoints in the final analysis of the Phase 3 ORIGIN 3 trial, preventing disease progression and stabilizing eGFR over 104 weeks. The drug, a weekly autoinjector that inhibits BAFF and APRIL, reduces proteinuria in high-risk adults with primary IgA nephropathy. The company presented these findings during the opening plenary and late-breaking sessions at the American Society of Nephrology Kidney Week 2026 in Denver. Trutakna works by decreasing immune complex formation and pathogenic IgA production while managing the effects of nephron loss.
Why it matters
Primary IgA nephropathy is a kidney disease that can lead to renal failure if proteinuria is not managed. Trutakna targets specific proteins to stop the production of harmful antibodies. The ORIGIN 3 results determine if the drug can move toward broader clinical use.
What is confirmed
- Trutakna met all endpoints in the Phase 3 ORIGIN 3 final analysis.
- The ORIGIN 3 trial demonstrated eGFR stabilization and prevention of disease progression over 104 weeks.
- Trutakna is a weekly autoinjector BAFF and APRIL inhibitor.
- Vera Therapeutics presented the ORIGIN 3 data at the American Society of Nephrology Kidney Week 2026 in Denver.
- The drug is designed to reduce proteinuria in high-risk patients with primary IgA nephropathy.
What to watch next
- Investor webcast on October 22 at 4:30 p.m. ET regarding ORIGIN 3 efficacy results
- Q3 2026 financial results webcast on November 5 at 4:30 p.m. ET
confidence 100%Sources used for this update (2)
- www.drugtopics.com — Trutakna Reduces Proteinuria in Adults With Primary IgAN
- finance.yahoo.com — Vera Therapeutics to Host ASN Kidney Week Investor Webcast ...
-
Trutakna Meets All Endpoints in Phase 3 IgA Nephropathy Trial
Vera Therapeutics confirmed that Trutakna met all endpoints in its Phase 3 ORIGIN 3 final analysis, demonstrating eGFR stabilization and prevention of disease progression over 104 weeks. The company presented this data, along with interim PIONEER Phase 2 results for multiple glomerular diseases, during late-breaking sessions and an opening plenary at the American Society of Nephrology Kidney Week 2026 in Denver. Trutakna is a weekly autoinjector BAFF and APRIL inhibitor designed to reduce proteinuria in high-risk patients with primary IgA nephropathy.
Why it matters
Vera is attempting to transition the drug from an accelerated proteinuria-based indication to full FDA approval. The company plans to submit a supplemental biologics license application in late 2026. This shift aims to position Trutakna as a disease-modifying therapy.
What is confirmed
- Trutakna met all endpoints in the Phase 3 IgA nephropathy trial final analysis.
- The final analysis confirmed eGFR stabilization and disease progression prevention over 104 weeks.
- Vera Therapeutics presented five company sponsored abstracts at ASN Kidney Week 2026.
- Presentations included final ORIGIN 3 efficacy data and interim PIONEER results in multiple glomerular diseases.
- Trutakna is a weekly autoinjector BAFF and APRIL inhibitor.
Still unconfirmed
- Vera Therapeutics stock closed at US$30.25 on 2 October 2026.
What to watch next
- Submission of the supplemental biologics license application in late 2026
- FDA decision on full approval for the IgA nephropathy indication
confidence 100%Sources used for this update (14)
- www.nbcnews.com — Michigan House District 3 Primary Results 2026
- www.clinicaltrialvanguard.com — TRUTAKNA Meets All Endpoints in Phase 3 IgA Nephropathy Trial ...
- simplywall.st — Did Kidney Trial Data Updates Just Shift Vera Therapeutics ...
- www.marketscreener.com — Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis ...
- finance.yahoo.com — Do Vera Therapeutics' (VERA) High-Profile IgAN Data Show ...
- simplywall.st — Vera Therapeutics (VERA) Heads Into ASN Kidney Week As Its ...
- en.wikipedia.org — Vera (TV series) - Wikipedia
- en.wikipedia.org — List of Vera episodes - Wikipedia
- secure.vera.com — Vera | Log In
- www.verahealth.ai — Vera Health - Evidence-Based Clinical Answers
- www.youtube.com — Vera - YouTube
- www.justwatch.com — Vera - watch tv show streaming online
-
Vera Therapeutics to present Trutakna Phase 3 data at ASN Kidney Week
Vera Therapeutics will deliver multiple presentations on the final efficacy analysis of Trutakna at the American Society of Nephrology Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The drug showed a 76% lower risk of kidney disease progression compared to placebo over two years in adults with primary IgA nephropathy. Vera intends to submit a supplemental biologics license application in late 2026 to move the drug from an accelerated proteinuria-based indication toward full FDA approval.
Why it matters
Trutakna targets primary IgA nephropathy, a condition that can lead to kidney failure. The ORIGIN 3 trial serves as the basis for transitioning the drug from temporary accelerated approval to a permanent license.
What is confirmed
- The ORIGIN 3 trial final efficacy analysis for Trutakna will be presented at ASN Kidney Week 2026 from October 22 to 25.
- The presentations will occur in Denver, Colorado.
- Trutakna demonstrated a 76% lower risk of kidney disease progression compared to placebo over two years.
- Vera Therapeutics plans a supplemental biologics license application in late 2026.
What to watch next
- The detailed data presentations at ASN Kidney Week from October 22 to 25
- The submission of the supplemental biologics license application in late 2026
confidence 100%Sources used for this update (2)
- www.marketscreener.com — Vera Therapeutics Announces Origin 3 Final Efficacy Analysis ...
- www.hcplive.com — 6 Nephrology Headlines You Missed in September 2026
-
Vera Therapeutics reports strong final Phase 3 results for kidney drug Trutakna
Vera Therapeutics met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 trial for Trutakna in adults with primary IgA nephropathy. The drug demonstrated a 76% lower risk of kidney disease progression compared to placebo over two years, while maintaining a safety profile generally comparable to placebo. Vera plans to use this data for a supplemental biologics license application in late 2026 to transition the drug from an accelerated proteinuria-based indication to full FDA approval. Results will be presented at ASN Kidney Week 2026 from October 22 to 25.
Why it matters
Trutakna is currently approved under an accelerated pathway for IgA nephropathy. Full approval would validate the drug's ability to preserve kidney function and reduce proteinuria over the long term. This development follows a period of stock volatility for Vera Therapeutics.
What is confirmed
- Trutakna met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 trial for adults with primary IgA nephropathy.
- The final ORIGIN 3 analysis showed a 76% lower risk of kidney disease progression versus placebo through two years.
- Vera Therapeutics plans to file a supplemental biologics license application in late 2026.
- The drug showed a safety profile generally comparable to placebo.
- Vera will deliver a late-breaking oral presentation on the ORIGIN 3 final efficacy analysis at ASN Kidney Week 2026 in Denver, Colorado.
What to watch next
- FDA decision on the supplemental BLA filing in late 2026
- Interim results from the PIONEER Phase 2 basket trial for adult IgAN and primary membranous nephropathy cohorts
- FDA decision on povetacicept on November 30
confidence 100%Sources used for this update (19)
- www.nbcnews.com — Washington House District 3 Primary Results 2026
- finance.yahoo.com — Vertex Posts Positive Phase II Data on Kidney Disease Drug
- simplywall.st — Will Positive Kidney Trial Results Change Vera Therapeutics ...
- www.marketbeat.com — Vera Therapeutics (VERA) FDA Approvals, PDUFA Dates & Drug ...
- simplywall.st — Is Vera Therapeutics (VERA) Cheap After TRUTAKNA Met All ...
- stockanalysis.com — Vera Therapeutics (VERA) Stock Price & Overview
- ctv.veeva.com — Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
- www.cancernetwork.com — Capivasertib and Fulvestrant for Patients With HR+/HER2− Advanced Breast Cancer: Final Overall Survival Results From the Phase 3 CAPItello-291 Trial
- www.hcplive.com — Atacicept Slows IgAN Decline to Physiologic Rate, With Sayna ...
- www.trialfriend.com — Atacicept vs Povetacicept | IgA Nephropathy 2026
- news.qq.com — Vera公布阿塞西普ORIGIN 3研究两年最终疗效数据：稳定eGFR，显著降低I...
- markets.businessinsider.com — Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the ...
-
Vera Therapeutics to seek FDA approval for Trutakna after Phase 3 success
Vera Therapeutics will apply for full FDA approval of Trutakna later in 2026 via a supplemental biologics license application. The drug met all prespecified endpoints in the final Phase 3 ORIGIN 3 trial for IgA nephropathy. Results indicate the treatment stabilizes kidney function and prevents disease progression. The company reported a favorable safety profile for the drug during the study.
Why it matters
Trutakna targets primary IgA nephropathy, a condition that can lead to kidney failure. The ORIGIN 3 trial ran for 104 weeks to measure the drug's impact on eGFR and disease progression. Full regulatory approval would allow the treatment to enter the commercial market.
What is confirmed
- Trutakna met all prespecified endpoints in the Phase 3 ORIGIN 3 trial for IgA nephropathy.
- The ORIGIN 3 study showed Trutakna stabilized kidney function and prevented disease progression.
- Vera Therapeutics plans to seek full FDA approval later in 2026.
What to watch next
- The submission of the supplemental biologics license application to the FDA
- The FDA decision on the full regulatory approval of Trutakna
confidence 100%Sources used for this update (4)
- www.nbcnews.com — Utah House District 3 Primary Results 2026
- finance.yahoo.com — Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints
- pro.thestreet.com — Top Stock Gainers
- www.nbcnews.com — Virginia House District 3 Primary Results 2026
-
Vera Therapeutics Reports Positive Phase 3 Results for Trutakna
Vera Therapeutics announced that its drug Trutakna (atacicept-vymj) stabilized kidney function and prevented disease progression in adults with primary IgA nephropathy. Final efficacy analysis from the two-year ORIGIN 3 Phase 3 trial shows the drug reduced the risk of IgAN progression by 76%. These results position the treatment for full regulatory approval. The data confirms that Trutakna stabilized eGFR and reduced the rate of kidney function decline over the 104-week study period.
Why it matters
IgA nephropathy is a kidney disease that can lead to progressive renal failure. Trutakna aims to slow this decline to prevent the need for dialysis or transplants. Vera Therapeutics currently faces deepening rivalry with Vertex in this therapeutic space.
What is confirmed
- Trutakna stabilized eGFR and prevented kidney disease progression through two years in the ORIGIN 3 trial.
- Final data from the ORIGIN 3 trial shows atacicept cut IgAN progression risk by 76%.
- Trutakna reduced the rate of kidney function decline in adults with primary IgA nephropathy.
- The ORIGIN 3 trial results are based on a final 104-week analysis.
Still unconfirmed
- Vera Therapeutics is experiencing a deepening rivalry with Vertex.
What to watch next
- Submission of Trutakna for full regulatory approval
- Official FDA or EMA decision on the drug's market entry
confidence 100%Sources used for this update (8)
- STAT — Vera kidney drug Trutakna shows strong final results in Phase 3 trial
- FirstWord Pharma — Positive data positions Vera's IgA nephropathy drug Trutakna for full approval
- Investor's Business Daily — Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened?
- Yahoo Finance — Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
- HCPLive — Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data
- pulse2.com — Vera Therapeutics Reports Positive Two-Year Phase 3 Trutakna Results
- www.statnews.com — U.S. reaches highest number of measles deaths in decades
- www.empr.com — ORIGIN 3: Atacicept Reduces Kidney Function Decline in IgAN
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community